Clinical trial · Interventional
Study of AS1411 in Advanced Solid Tumours
Phase I Open Label Study of AS1411 in Advanced Solid Tumours
NCT00881244CI-TRIAL-00002214completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Phase I open label study of AS1411 in advanced solid tumours. Objectives include determining the MTD and DLT of AS1411, to determine the PK profile of AS1411 and to obtain preliminary evidence of clinical and biological responses to AS1411 therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AS1411 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- AS1411
- interventionNames
- Drug: AS1411
Primary outcomes (1)
- measure
- To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of AS1411
Secondary outcomes (2)
- measure
- To determine the pharmacokinetic (PK) distribution and profile of AS1411
- measure
- To obtain preliminary evidence of clinical and biological responses to AS1411
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced solid tumours that were refractory to conventional/standard treatment * Age \>/ 18 years * ECOG performance status \</ 2 (Karnofsky \>/60% * Life expectancy \>/ 8 weeks * Adequate organ and marrow function Exclusion Criteria: * Radiotherapy or chemotherapy in the 4 weeks before study entry (6 weeks for nitrosourea or mitomycin C * Lack of recovery from adverse events (AEs) caused by agents administered before study entry; current use of other investigational agent(s) * Uncontrolled brain metastases including a need for corticosteroid therapy * Pregnancy * Uncontrolled intercurrent illness * Psychiatric illness/social situations that could limit compliance
References
Publications (0)
Data not yet available
No reference posted for this study.